Baim DS, Detre K, Kent K Problems in the development of new devices for coronary intervention: possible role for a multicenter registry. J Am Coll Cardiol. 1989 Nov 1;14(5):1389-92.
Bentivoglio LG, Detre K, Yeh W, Williams DO, Kelsey SF, Faxon DP Outcome of percutaneous transluminal coronary angioplasty in subsets of unstable angina pectoris. A report of the 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. J Am Coll Cardiol. 1994 Nov 1;24(5):1195-206.
Bentivoglio LG, Van Raden MJ, Kelsey SF, Detre KM Percutaneous transluminal coronary angioplasty (PTCA) in patients with relative contraindications: results of the National Heart, Lung, and Blood Institute PTCA Registry. Am J Cardiol. 1984 Jun 15;53(12):82C-88C.
Bock HE [The weight of the physician's experience]. Ther Ggw. 1981 Sep;120(9):763-87. German.
Bourassa MG, Holubkov R, Yeh W, Detre KM Strategy of complete revascularization in patients with multivessel coronary artery disease (a report from the 1985-1986 NHLBI PTCA Registry). Am J Cardiol. 1992 Jul 15;70(2):174-8.
Bourassa MG, Yeh W, Holubkov R, Sopko G, Detre KM Long-term outcome of patients with incomplete vs complete revascularization after multivessel PTCA. A report from the NHLBI PTCA Registry. Eur Heart J. 1998 Jan;19(1):103-11.
Cannan CR, Yeh W, Kelsey SF, Cohen HA, Detre K, Williams DO Incidence and predictors of target vessel revascularization following percutaneous transluminal coronary angioplasty: a report from the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Am J Cardiol. 1999 Jul 15;84(2):170-5.
Cowley MJ, Dorros G, Kelsey SF, Van Raden M, Detre KM Emergency coronary bypass surgery after coronary angioplasty: the National Heart, Lung, and Blood Institute's Percutaneous Transluminal Coronary Angioplasty Registry experience. Am J Cardiol. 1984 Jun 15;53(12):22C-26C.
Detre KM, Myler RK, Kelsey SF, Van Raden M, To T, Mitchell H Baseline characteristics of patients in the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Am J Cardiol. 1984 Jun 15;53(12):7C-11C.
Faxon DP, Kelsey SF, Ryan TJ, McCabe CH, Detre K Determinants of successful percutaneous transluminal coronary angioplasty: report from the National Heart, Lung, and Blood Institute Registry. Am Heart J. 1984 Oct;108(4 Pt 1):1019-23.
Faxon DP, Vogel R, Yeh W, Holmes DR Jr, Detre K Value of visual versus central quantitative measurements of angiographic success after percutaneous transluminal coronary angioplasty. NHLBI PTCA Registry Investigators. Am J Cardiol. 1996 May 15;77(12):1067-72.
Holmes DR Jr, Kip KE, Kelsey SF, Detre KM, Rosen AD Cause of death analysis in the NHLBI PTCA Registry: results and considerations for evaluating long-term survival after coronary interventions. J Am Coll Cardiol. 1997 Oct;30(4):881-7.
Hong MK, Popma JJ, Baim DS, Yeh W, Detre KM, Leon MB Frequency and predictors of major in-hospital ischemic complications after planned and unplanned new-device angioplasty from the New Approaches to Coronary Intervention (NACI) registry. Am J Cardiol. 1997 Nov 20;80(10A):40K-49K.
Kelsey SF, Miller DP, Holubkov R, Lu AS, Cowley MJ, Faxon DP, Detre KM Results of percutaneous transluminal coronary angioplasty in patients greater than or equal to 65 years of age (from the 1985 to 1986 National Heart, Lung, and Blood Institute's Coronary Angioplasty Registry). Am J Cardiol. 1990 Nov 1;66(15):1033-8.
Marks DS, Mensah GA, Kennard ED, Detre K, Holmes DR Jr Race, baseline characteristics, and clinical outcomes after coronary intervention: The New Approaches in Coronary Interventions (NACI) registry. Am Heart J. 2000 Jul;140(1):162-9.
Moses JW, Moussa I, Popma JJ, Sketch MH Jr, Yeh W Risk of distal embolization and infarction with transluminal extraction atherectomy in saphenous vein grafts and native coronary arteries. NACI Investigators. New Approaches to Coronary Interventions. Catheter Cardiovasc Interv. 1999 Jun;47(2):149-54.
Mullin SM, Passamani ER, Mock MB Historical background of the National Heart, Lung, and Blood Institute Registry for Percutaneous Transluminal Coronary Angioplasty. Am J Cardiol. 1984 Jun 15;53(12):3C-6C.
Reeder GS, Holmes DR Jr, Detre K, Costigan T, Kelsey SF Degree of revascularization in patients with multivessel coronary disease: a report from the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation. 1988 Mar;77(3):638-44.
Ruocco NA Jr, Ring ME, Holubkov R, Jacobs AK, Detre KM, Faxon DP Results of coronary angioplasty of chronic total occlusions (the National Heart, Lung, and Blood Institute 1985-1986 Percutaneous Transluminal Angioplasty Registry). Am J Cardiol. 1992 Jan 1;69(1):69-76.
Scott NA, Kelsey SF, Detre K, Cowley M, King SB 3rd Percutaneous transluminal coronary angioplasty in African-American patients (the National Heart, Lung, and Blood Institute 1985-1986 Percutaneous Transluminal Coronary Angioplasty Registry). Am J Cardiol. 1994 Jun 15;73(16):1141-6.
Singh M, Rihal CS, Selzer F, Kip KE, Detre K, Holmes DR Validation of Mayo Clinic risk adjustment model for in-hospital complications after percutaneous coronary interventions, using the National Heart, Lung, and Blood Institute dynamic registry. J Am Coll Cardiol. 2003 Nov 19;42(10):1722-8.
Srinivas VS, Brooks MM, Detre KM, King SB 3rd, Jacobs AK, Johnston J, Williams DO Contemporary percutaneous coronary intervention versus balloon angioplasty for multivessel coronary artery disease: a comparison of the National Heart, Lung and Blood Institute Dynamic Registry and the Bypass Angioplasty Revascularization Investigation (BARI) study. Circulation. 2002 Sep 24;106(13):1627-33.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.